+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 50Years - 80Years
All Genders
ID07317934

Phase III Study to Evaluate LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration Compared to Aflibercept

Led by Innostellar Biotherapeutics Co.,Ltd · Updated on 2026-08-06

388

Participants Needed

36

Research Sites

222 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of a gene therapy called LX102 in people aged 50 to 80 years with neovascular age-related macular degeneration nAMD, a condition affecting the eyes. This Phase III study compares a single subretinal injection of LX102 to a standard treatment, aflibercept, to see how well each improves vision over time. The studys main goal is to measure changes in best-corrected visual acuity BCVA around one year after treatment. Participants receive either one subretinal injection of LX102 or a series of aflibercept injections, which include three monthly doses followed by injections every eight weeks. The study is randomized and open-label, meaning participants are assigned by chance to one of the two treatment groups, and both the participants and researchers know which treatment is given. The treatment period and follow-up assessments extend to at least 56 weeks, with additional evaluations up to week 104. Throughout the study, participants will have their vision tested regularly to monitor changes in BCVA and central subfield thickness CST of the retina. Researchers will also check for retinal fluid presence using imaging and record any need for supplemental anti-VEGF injections. Safety is closely monitored by tracking any eye-related or other serious adverse events. The study lasts for over six years, including long-term monitoring to better understand the treatment effects and safety.

CONDITIONS

Brief Title

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here